Rosa Maria Iacobazzi

Dr. Rosa Maria Iacobazzi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
LPLetizia Porcelli
Letizia Porcelli
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
RFRoberta Di Fonte
Roberta Di Fonte
Simona Serrati'Simona Serrati'
Simona Serrati'
AIAngelica Intini
Angelica Intini
Nicola SilvestrisNicola Silvestris
Nicola Silvestris
Tumor–stroma interactions are of key importance for pancreatic ductal adenocarcinoma (PDAC) progression. Our aim was to investigate whether cancer associated fibroblasts (CAFs) and mast cells (MC) affected the sensitivity of PDAC cells to gemcitabine/nabpaclitaxel (GEM/NAB). For this purpose, the combination cytotoxicity and the effect on tumor invasion and angiogenesis were evaluated with or without a conditioned medium from the mast cell line HMC-1 (human mast cell line-1 cells) and CAFs. Beside the clinical outcome of a homogenous population of PDAC patients, receiving GEM/NAB, was correlated to the circulating levels of mast cell tryptase and to a panel of inflammatory and immunosuppressive cytokines. CAFs neither affected drugs’ cytotoxicity nor the inhibition of angiogenesis, but promoted tumor cell invasion. The MC instead, caused resistance to drugs by reducing apoptosis, by activating the TGF-β signalling and by promoting tumor invasion. Indeed, the inhibition of TβRI serine/threonine kinase activity by galunisertib restored drugs cytotoxicity. Moreover, MC induced the release of TGF-β1, and increased expression of PAR-2, ERK1/2 and Akt activation. Accordingly, TGF-β1, tryptase and other pro-inflammatory and immunosuppressive cytokines increased in the unresponsive patients. In conclusion, MC play a pivotal role in the resistance to GEM/NAB. A correlation between high level of circulating pro-inflammatory/ immunosuppressive cytokines and unresponsiveness was found in PDAC patients.

4 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AAAntonella Argentiero
Antonella Argentiero
SSSimona De Summa
Simona De Summa
RFRoberta Di Fonte
Roberta Di Fonte
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
LPLetizia Porcelli
Letizia Porcelli
Antonio Giovanni SolimandoAntonio Giovanni Solimando
Antonio Giovanni Solimando
Over the past several years there has been much debate with regards to the prognostic and clinical significance of pancreatic ductal adenocarcinoma (PDAC) with lymph nodes metastasis. The PDAC gene expression knowledge and the biologic alterations underlying the lymph node involvement convey a clinical implication in dealing with the theranostic window. To this end, we provide an original bioinformatic dissection of the gene expression differences of PDAC according to the nodal involvement from a large public available dataset. Comprehensive transcriptomic analysis from 143 RNA-seq patient’s derived samples indicated that WNT increased activation and a peculiar immune microenvironment identify subjects with nodal involvement. In frame of this thinking, we validated the WNT pathway role in increasing the likelihood of lymphatic dissemination in vitro. Moreover, we demonstrated for the first time in a PDAC model the potential therapeutic window that XAV-939—a specific WNT pathway inhibitor—has in re-educating a tumor-permissive immune system. Finally, we outline the potential implication on bystander molecular drivers exerted by WNT molecular inhibition, providing a picture of the proteomic oncogenic landscape changes elicited by XAV-939 on PDAC cells and their clinical implication. Our findings hold the promise to identify novel immune-based therapeutic strategies targeting WNT to enhance PDAC cytotoxicity and restore anti-PDAC immunity in node-positive disease.

1 February 2022 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
FVFabio Vischio
Fabio Vischio
Ilaria ArduinoIlaria Arduino
Ilaria Arduino
FCFabio Canepa
Fabio Canepa
VLValentino Laquintana
Valentino Laquintana
Nunzio DenoraNunzio Denora
Nunzio Denora

22 June 2019 in Preprints.org
Verified
Preprint
Open access
AAAntonella Argentiero
Antonella Argentiero
SSSimona De Summa
Simona De Summa
RFRoberta Di Fonte
Roberta Di Fonte
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
LPLetizia Porcelli
Letizia Porcelli
Antonio Giovanni SolimandoAntonio Giovanni Solimando
Antonio Giovanni Solimando
Over the past several years there has been much debate with regards to the prognostic and clinical significance of pancreatic ductal adenocarcinoma (PDAC) with lymph nodes metastasis. The PDAC gene-expression knowledge and the biologic alterations underlying the lymph node involvement convey a clinical implication in dealing with the theranostic window.To this end, we provide an original bioinformatic dissection of the gene-expression differences of PDAC according to the nodal involvement from a large public available dataset. Comprehensive transcriptomic analysis from 143 RNA-seq patient’s derived samples indicated that WNT increased activation and a peculiar immune-microenvironment identify subjects with nodal involvement.In frame of this thinking, we validated the WNT pathway role in increasing the likelihood of lymphatic dissemination in vitro. Moreover, we demonstrated for the first time in a PDAC model the potential therapeutic window that XAV-939, a specific WNT pathway inhibitor, has in re-educating a tumour permissive immune system. Finally, we outline the potential implication on bystander molecular drivers exerted by WNT molecular inhibition, providing a picture of the proteomic oncogenic landscape changes elicited by XAV-939 on PDAC cells and their clinical implication. Our findings hold the promise to identify novel immune-based therapeutic strategies targeting WNT to enhance PDAC cytotoxicity and restore anti-PDAC immunity in nodes-positive disease.

14 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DFDafina Fondaj
Dafina Fondaj
Ilaria ArduinoIlaria Arduino
Ilaria Arduino
Angela LopedotaAngela Lopedota
Angela Lopedota
Nunzio DenoraNunzio Denora
Nunzio Denora
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
Nanomedicines have made remarkable advances in recent years, addressing the limitations of traditional therapy and treatment methods. Due to their improved drug solubility, stability, precise delivery, and ability to target specific sites, nanoparticle-based drug delivery systems have emerged as highly promising solutions. The successful interaction of nanoparticles with biological systems, on the other hand, is dependent on their intentional surface engineering. As a result, biomimetic nanoparticles have been developed as novel drug carriers. In-depth knowledge of various biomimetic nanoparticles, their applications, and the methods used for their formulation, with emphasis on the microfluidic production technique, is provided in this review. Microfluidics has emerged as one of the most promising approaches for precise control, high reproducibility, scalability, waste reduction, and faster production times in the preparation of biomimetic nanoparticles. Significant advancements in personalized medicine can be achieved by harnessing the benefits of biomimetic nanoparticles and leveraging microfluidic technology, offering enhanced functionality and biocompatibility.

9 December 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
IAIlaria Arduino
Ilaria Arduino
RFRoberta Di Fonte
Roberta Di Fonte
MTMattia Tiboni
Mattia Tiboni
LPLetizia Porcelli
Letizia Porcelli
Simona Serrati'Simona Serrati'
Simona Serrati'
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
Optimizing current therapies is among next steps in metastatic melanoma (MM) treatment landscape. The innovation of this study is the design of production process by microfluidics of cell membrane (CM)-modified nanoparticles (NPs), as an emerging biomimetic platform that allows for reduced immune clearance, long blood circulation time and improved specific tumor targeting. To achieve melanoma selectivity, direct membrane fusion between synthetic liposomes and CMs extracted from MM cell line was performed by microfluidic sonication approach, then the hybrid liposomes were loaded with cobimetinib (Cob) or lenvatinib (Lenva) targeting agents and challenged against MM cell lines and liver cancer cell line to evaluate homotypic targeting and antitumor efficacy. Characterization studies demonstrated the effective fusion of CM with liposome and the high encapsulation efficiency of both drugs, showing the proficiency of microfluidic-based production. By studying the targeting of melanoma cells by hybrid liposomes versus liposomes, we found that both NPs entered cells through endocytosis, whereas the former showed higher selectivity for MM cells from which CM was extracted, with 8-fold higher cellular uptake than liposomes. Hybrid liposome formulation of Cob and Lenva reduced melanoma cells viability to a greater extent than liposomes and free drug and, notably, showed negligible toxicity as demonstrated by bona fide haemolysis test. The CM-modified NPs presented here have the potential to broaden the choice of therapeutic options in MM treatment.